Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 7/20 | 0.41 |
| ▸ | TPMT | P51580 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | UNG | P13051 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA7 | P43166 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847370 | 0.82 | TTR (0.62) | TTRTPMTPOLBKDM4EHCAR1 | |
| SCHEMBL23242900 | 0.80 | LMNA (0.40) | ERN1HTTALDH1A1CA2LMNA | |
| SCHEMBL25385602 | 0.79 | TTR (0.67) | TTRERN1TPMTPOLBL3MBTL1 | |
| SCHEMBL22400345 | 0.79 | TTR (0.50) | TTRERN1TPMTPOLBCTDSP1 | |
| SCHEMBL30574966 | 0.79 | TTR (0.67) | TTRERN1TPMTPOLBL3MBTL1 | |
| SCHEMBL29945684 | 0.78 | ERN1 (0.47) | ERN1KDM4EALDH1A1LMNA | |
| SCHEMBL332788 | 0.78 | ERN1 (0.47) | ERN1KDM4EALDH1A1LMNA | |
| SCHEMBL1724284 | 0.76 | TTR (0.56) | TTRTPMTPOLBKDM4EHTT | |
| SCHEMBL30753326 | 0.76 | TTR (0.56) | TTRTPMTPOLBKDM4EHTT | |
| SCHEMBL16122465 | 0.75 | TTR (0.54) | TTRTPMTPOLBKDM4EHCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-06-18 | — | — | US | disclosed |
| US-11566028-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-11566028-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| WO-2021146424-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021146424-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-07-22 | — | — | WO | disclosed |
| US-20210214366-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-07-15 | — | — | US | disclosed |
| US-20210214366-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-07-15 | — | — | US | disclosed |
| WO-2021076728-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076728-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20210115053-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-04-22 | — | — | US | disclosed |
| US-20210115053-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115053-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | TTR 4743/4885ERN1 3469/4885TPMT 1575/4885 |
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR3, FGFR2, FGFR1 | TTR 4743/4885ERN1 3460/4885TPMT 1233/4885 |
| US-20210214366-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR3, FGFR2, FGFR1 | TTR 4743/4885ERN1 3460/4885TPMT 1233/4885 |
| US-11566028-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | TTR 4743/4885ERN1 3469/4885TPMT 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.